I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 0.9397 USD -2.01% Market Closed
Market Cap: 76m USD
Have any thoughts about
I-Mab?
Write Note

I-Mab
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

I-Mab
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
I-Mab
NASDAQ:IMAB
Net Income (Common)
-ÂĄ1.5B
CAGR 3-Years
N/A
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
ÂĄ1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Net Income (Common)
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
ÂĄ6B
CAGR 3-Years
-6%
CAGR 5-Years
26%
CAGR 10-Years
48%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
ÂĄ1.9B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

I-Mab
Glance View

Market Cap
76m USD
Industry
Biotechnology

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

IMAB Intrinsic Value
0.7454 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is I-Mab's Net Income (Common)?
Net Income (Common)
-1.5B CNY

Based on the financial report for Dec 31, 2023, I-Mab's Net Income (Common) amounts to -1.5B CNY.

What is I-Mab's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-29%

Over the last year, the Net Income (Common) growth was 42%.

Back to Top